Duluth, Ga. – June 22, 2012 – Merial’s PUREVAX® Recombinant FeLV – the newest addition to the only complete line of non-adjuvanted feline vaccines in the U.S. - is now available. Delivered subcutaneously by needle injection, PUREVAX Recombinant FeLV features improved potency, providing excellent protection with a lower antigen concentration than PUREVAX Recombinant Leukemia Vaccine.
Feline leukemia virus (FeLV) can lead to contagious, incurable and lethal disease. FeLV causes cancer in about 20 percent of infected cats and contributes to the development of other infectious diseases and anemia by suppressing the immune system and function of bone marrow. The American Association of Feline Practitioners (AAFP) recommends FeLV vaccination for all kittens, and an annual booster inoculation is recommended for cats considered to be at risk of exposure – which include those not housed strictly indoors.(5)
“PUREVAX Recombinant FeLV offers the convenience of subcutaneous delivery with the efficacy and safety you would expect from a non-adjuvanted recombinant vaccine,” said Dr. Robert Menardi, marketing director for Pet Vaccines, Merial. “Non-adjuvanted vaccines may help reduce the potential risks associated with adjuvants, which include injection site reaction, injection site granuloma or chronic inflammation.”(6)
Merial developed PUREVAX Recombinant FeLV in response to customer desire for a safe, efficacious, non-adjuvanted product with convenient route of administration. PUREVAX Recombinant FeLV uses recombinant canarypox-vectored vaccine technology, which stimulates FeLV-specific cell-mediated immunity and is proven effective in the face of severe challenge.
PUREVAX Recombinant FeLV is recommended for the vaccination of healthy cats 8 weeks or older as an aid in the prevention of disease due to feline leukemia virus. For primary vaccination, cats should receive two 1-ml dose vaccinations, three weeks apart. Annual booster injections are recommended in cats considered to be at risk of exposure. Diagnostic testing for FeLV prior to vaccination also is recommended.
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,600 people and operates in more than 150 countries worldwide. Its 2011 sales were more than $2.8 billion.
Merial is a Sanofi company.
®PUREVAX is a registered trademark of Merial. ©2012 Merial Limited, Duluth, GA. All rights reserved.
1 Merial Data on File.
2 Feline Leukemia Virus and Related Diseases (Feline lymphoma and leukemia, Lymphosarcoma). In: Kahn CM, ed. The Merck Veterinary Manual. 10th ed. Whitehouse Station, NJ: Merck & Co., Inc; 2010: 718-722.
3 Schaer M. Clinical Medicine of the Dog and Cat. London: Mansom Publishing; 2003: 100.
4 Hartmann K. Chapter 13 – Feline Leukemia Virus Infection. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. Philadelphia: WB Saunders Co., 2006: 105-131.
5 Richards JR, et al. The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel Report. JAVMA 2006; 229(9); 1405-1441.
6 El Garch HE, Richard S, Piras F, et al: Feline Leukemia Virus (FeLV)-specific IFNY+T-cell responses are induced in cats following transdermal vaccination with a recombinant FeLV vaccine. Intern J Appl Res Vet Med. 2006;4(2);100-108
7 Grosenbaugh DA, Leard T, Pardo MC. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine. JAVMA. 2006;228(5);726-727
8 Poulet H, Brunet S, Boularand C, et al. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet Rec. 2003;153(3);141-145